Search | Clinical Trials Finder

Conditions: Pulmonary Arterial Hypertension
Interventions: Seralutinib, Gereic Dry Powder Inhaler; Drug · Device
Lead sponsor: Gossamer Bio USA, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 33
States / cities: Fresno, California • Los Angeles, California • Sacramento, California + 26 more

Conditions: Perennial Allergic Rhinitis, Allergic Rhinitis, Hay Fever
Interventions: Ciclesonide; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Respiratory Depression, Respiratory Failure, Ventilatory Depression
Interventions: Endotracheal Tube Fastener; Device
Lead sponsor: Hollister Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 3
States / cities: Gresham, Oregon • Portland, Oregon • Vancouver, Washington

Conditions: Severe Acute Respiratory Syndrome Coronavirus 2
Interventions: Aerolized Hydroxychloroquine Sulfate, Placebo; Drug · Other
Lead sponsor: Pulmoquine Therapeutics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetes Mellitus, Type 2
Interventions: Exubera (inhaled insulin), 8-point glucose diary (to assess pre- and post prandial glucoses), Meal Tolerance Test, 24-hour continuous glucose monitoring (at select sites), Pulmonary Function Testing, Hypoglycemic Event Monitoring, Laboratory Assessments, Nutritional Counseling and Diabetes Education; Drug · Procedure · Behavioral
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 16
States / cities: Birmingham, Alabama • Los Angeles, California • New Britain, Connecticut + 13 more

Conditions: Chronic Cough
Interventions: ADX-629, Placebo; Drug
Lead sponsor: Aldeyra Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 14
States / cities: San Diego, California • San Jose, California • Hollywood, Florida + 11 more

Conditions: Periodic Fever, Aphthous Stomatitis, Pharyngitis, And Cervical Adenitis (Pfapa), Obstructive Sleep Apnea, Tonsillitis, Tonsil Disorder, Sleep Disordered Breathing
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Month to 99 Years
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2038
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Indianapolis, Indiana • Bethesda, Maryland

Conditions: Healthy
Interventions: Nose-only breathing, Mouth-only breathing; Behavioral
Lead sponsor: Florida State University; Other
Eligibility: 18 Years to 30 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Tallahassee, Florida

Conditions: Asthma
Interventions: Roflumilast; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 70 Years
Enrollment: 2,054 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Cities in Georgia, Georgia

Conditions: Pharmacokinetics, Epinephrine, Albuterol, Asthma, Anaphylaxis
Interventions: Epinephrine (0.125 mg/inhalation), Epinephrine Injection Auto-Injector (0.3mg/0.3mL), Albuterol Sulfate (0.09 mg/inhalation); Combination Product
Lead sponsor: Amphastar Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Cypress, California

Conditions: Cleft Palate
Interventions: Polysomnography; Procedure
Lead sponsor: University of Michigan; Other
Eligibility: 6 Years to 15 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: COVID-19
Interventions: Niclosamide, Placebo; Drug
Lead sponsor: NeuroBo Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 8
States / cities: Sheffield, Alabama • Irvine, California • Jacksonville, Florida + 5 more

Conditions: Narcolepsy, Obstructive Sleep Apnea, Excessive Daytime Somnolence, Excessive Sleepiness, Postpartum
Interventions: Solriamfetol 150 mg Oral Tablet; Drug
Lead sponsor: Axsome Therapeutics, Inc.; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Raleigh, North Carolina

Conditions: Atrial Fibrillation
Interventions: MyTAP oral appliance plus mouth shield; Device
Lead sponsor: Texas A&M University; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Nausea
Interventions: Inhaled isopropyl alcohol, Oral ondansetron, Inhaled normal saline, Oral placebo; Drug
Lead sponsor: Brooke Army Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Obstructive Sleep Apnea
Interventions: EVO Sleep and Snore Device; Device
Lead sponsor: ProSomnus Sleep Technologies; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: New York, New York • Dallas, Texas

Conditions: Obstructive Sleep Apnea
Interventions: Not listed
Lead sponsor: University of New Mexico; Other
Eligibility: 20 Years to 40 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Pulmonary Arterial Hypertension
Interventions: GB002 (seralutinib), Generic Dry Powder Inhaler; Drug · Device
Lead sponsor: Gossamer Bio USA, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 15
States / cities: Sacramento, California • Santa Barbara, California • Jacksonville, Florida + 11 more

Conditions: Primary Ciliary Dyskinesia
Interventions: VX-371, Hypertonic Saline, Placebo (0.17% saline), VX-371 + HS, Ivacaftor; Drug
Lead sponsor: Parion Sciences; Industry
Eligibility: 12 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 21
States / cities: Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 18 more

Conditions: Pulmonary Hypertension Associated With Interstitial Lung Disease
Interventions: Placebo, Seralutinib, Generic Dry Powder Inhaler; Drug · Device
Lead sponsor: GB002, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Fresno, California • Albuquerque, New Mexico • Richmond, Virginia

Conditions: Obstructive Sleep Apnea (OSA), Oral Applliance Therapy
Interventions: The study will assess the feasibility of incorporating the PLATO questionnaire into a dental sleep practice. The PLATO questionnaire was developed as a patient reported outcome measure; Other
Lead sponsor: Nevada Dental Sleep; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Henderson, Nevada

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Levosimendan, Placebo for levosimendan; Drug
Lead sponsor: Orion Corporation, Orion Pharma; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 496 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 48
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 35 more

Conditions: PAH
Interventions: oral treprostinil; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 7 Years to 17 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 9
States / cities: Palo Alto, California • San Francisco, California • Aurora, Colorado + 6 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: BI 1744 CL plus tiotropium bromide, Respimat® Inhaler; Drug · Device
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 5
States / cities: Clearwater, Florida • Tampa, Florida • Philadelphia, Pennsylvania + 2 more

Search by objective public record fields.

Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)

Safety of Ciclesonide Nasal Spray Administered With Inhaled Fluticasone Dipropionate/Salmeterol in Adults With Perennial Allergic Rhinitis (BY9010/M1-409)

Assessment of a Oral Endotracheal Tube Fastener on Patients Intubated With Oral Endotracheal Tubes

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Orally Inhaled Aerosolized Hydroxychloroquine Sulfate in Healthy Adult Volunteers

US Inhaled Insulin Dose Titration Study

A Clinical Trial to Evaluate the Safety and Efficacy in Subjects With Chronic Cough

Evaluating the Genetics and Immunology of Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis (PFAPA) Syndrome and Other Tonsil Disorders

Comparing Nose & Mouth Breathing During Exercise

Efficacy and Safety of Oral Roflumilast Taken With Low Dose Inhaled Corticosteroids in Patients With Asthma (12 to 70 y) (BY217/M2-013)

Study of Drug Exposure in Systemic Circulation of Primatene Mist by Oral Inhalation, Versus Epinephrine Injection by Intramuscular Injection and ProAir by Oral Inhalation in Healthy Individuals

Sleep and Behavior in Children With Cleft Palate

Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients

Evaluate Sunosi® PK in Breast Milk and Plasma of Healthy Postpartum Women Following Single Dose Oral Administration

Effect of Oral Appliance Therapy on Atrial Fibrillation

Isopropyl Alcohol vs Ondansetron for Nausea in the Emergency Department

Severe Label Expansion for EVO Products Trial

Quantitative Genioglossal Muscle Strength in Obstructive Sleep Apnea (OSAS)

Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)

Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia

Efficacy and Safety of Seralutinib in Adult Subjects With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Application of the Patient-reported Longitudinal Assessment Tool for OSA (PLATO) Questionnaire in Oral Appliance Therapy for Obstructive Sleep Apnea

Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS

Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years

Efficacy and Safety of 4 Weeks of Treatment With Orally Inhaled BI1744/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease (COPD)